Hypera (OTCMKTS:HYPMY) Releases Quarterly Earnings Results

Hypera (OTCMKTS:HYPMY) released its quarterly earnings results on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, Zacks reports. Hypera had a return on equity of 13.18% and a net margin of 20.04%. The firm had revenue of $258.56 million for the quarter.

Hypera Stock Performance

HYPMY stock opened at $3.62 on Friday. The business’s 50-day moving average is $3.27 and its two-hundred day moving average is $3.74. Hypera has a fifty-two week low of $2.64 and a fifty-two week high of $6.90. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.81 and a quick ratio of 1.41.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.